<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02381158</url>
  </required_header>
  <id_info>
    <org_study_id>0000573</org_study_id>
    <nct_id>NCT02381158</nct_id>
  </id_info>
  <brief_title>Nebulized Beclomethasone Dipropionate Improves Respiratory Lung Function in Preschool Children With Recurrent Wheezing</brief_title>
  <official_title>Nebulized Beclomethasone Dipropionate Improves Respiratory Lung Function in Preschool Children With Recurrent Wheezing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-centre, open label study, aiming to evaluate the efficacy of beclomethasone
      dipropionate applied for 12 weeks with a dose of 400 µg twice a day (total dose 800 µg
      nebulized), on airway resistance and reactances (measured with Rint and FOT techniques) in
      children with recurrent wheezing, aged 2-5 years. In addition, clinic score as frequency of
      symptoms and exacerbations, will be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lung fuction with Rint and FOT</measure>
    <time_frame>12 Weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Wheezing</condition>
  <arm_group>
    <arm_group_label>Nebulized Beclomethasone dipropionate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nebulized Beclomethasone dipropionate applied for 12 weeks with a dose of 400 µg twice a day (total dose 800 µg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebulized beclomethasone dipropionate</intervention_name>
    <description>Nebulized beclomethasone dipropionate applied for 12 weeks with a dose of 400 µg twice a day (total dose 800 µg)</description>
    <arm_group_label>Nebulized Beclomethasone dipropionate</arm_group_label>
    <other_name>BDP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed and subscribed consent before any procedure

          -  Age range : 2 - ≤5 years

          -  Male and female patients

          -  Recurrent wheezing affected ( ≥ 4 episodes in the last 12 months)

          -  PAI positive (at least one primary and two secondary ):

        Primary:

          1. one parent with asthma

          2. Atopic Dermatitis

          3. sensibilisation to air allergen

        Secondary:

          1. Food sensibilization

          2. wheezing also not during the infective episodes

          3. eosinophilia (&gt;4%)

        Exclusion Criteria:

          -  story of severe wheeze requiring hospitalization

          -  treatment with inhaled glucocorticoids during the previous 4 weeks or with oral
             glucocorticoids in the previous 8 weeks

          -  structural abnormalities of the lungs (tracheobronchial bronchomalacia, external
             compressions, etc)

          -  Persistent infections

          -  aspiration lung disease (gastroesophageal reflux disease, etc.)

          -  Cystic fibrosis

          -  prematurity or bronchopulmonary dysplasia

          -  Tuberculosis

          -  primary ciliary dyskinesia

          -  congenital heart disease

          -  pulmonary foreign body

          -  bronchiectasis

          -  Immunodeficit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2015</study_first_submitted>
  <study_first_submitted_qc>March 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2015</study_first_posted>
  <last_update_submitted>January 19, 2017</last_update_submitted>
  <last_update_submitted_qc>January 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy</investigator_affiliation>
    <investigator_full_name>Stefania La Grutta, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Wheezing</keyword>
  <keyword>Children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Sounds</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Beclomethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

